GHK-Cu is the copper(II) complex of GHK (glycyl-L-histidyl-L-lysine), a three-amino-acid peptide first isolated from human plasma that binds copper ions with high affinity. GHK is also found in saliva and urine, and its levels are reported to decline with age. Laboratory and animal studies have examined it for effects on wound repair, extracellular matrix remodelling, inflammation and gene expression, and the small number of human studies have been topical (skin-applied) products.
Research overview
GHK-Cu is a naturally occurring copper-binding tripeptide studied for skin, wound-healing and anti-inflammatory effects. It has a long history of use in topical cosmetic formulations and some published human skin studies, but it is not organized into a conventional Phase 1–3 drug development program.
Mechanism of action
GHK binds copper(II) ions and spontaneously forms the GHK-Cu complex. One proposed idea is that GHK sequences are released from collagen at sites of tissue injury (the GHK triplet is present in the alpha-2(I) chain of type I collagen) and act as a local signal for repair. This is a hypothesis raised by the original cell-culture work, not an established mechanism in people [PMID 3169264].
In cultured cells and rat wound models, GHK-Cu has been reported to increase collagen and glycosaminoglycan synthesis and extracellular matrix accumulation, and to raise type I and III collagen mRNA without raising TGF-beta mRNA in the wound-chamber model [PMID 8227353]. In keratinocyte cultures and skin-equivalent models it was reported to increase proliferation and the expression of integrins, p63 and PCNA [PMID 19319546]. These are experimental findings; their relevance to intact human skin has not been established.
Reviews authored by Pickart and colleagues report that GHK-Cu modulates the expression of a large number of genes (stated as at least 4,000), based on computational gene-expression database analysis rather than clinical measurement. These reviews come from overlapping authors and should be treated as hypothesis-generating until independently replicated [PMID 26236730][PMID 29986520].
Anti-inflammatory and antioxidant actions have been reported in one mouse lipopolysaccharide-induced lung injury model and in macrophage cultures, where GHK-Cu was associated with lower ROS, TNF-alpha and IL-6 and reduced NF-kB p65 and p38 MAPK signalling. The certainty of this mechanism in humans is low [PMID 27517151].
Adult human evidence
All adult human studies identified and verified here involved topical (skin-applied) products. No verified human study of injected or other systemic GHK-Cu use was found, and nothing in this section should be read as evidence for injected or systemic use.
One small randomised study applied skin-care regimens with or without GHK-Cu after CO2 laser resurfacing of the skin around the mouth. Thirteen patients completed the study. Computer analysis and blinded evaluators observed no statistically significant difference between groups in the resolution of erythema, and objective assessment found no difference in wrinkles or overall skin quality. A questionnaire did report higher self-assessed skin quality in the GHK-Cu group (P = .04). With only 13 completers, the study was small, and the self-reported benefit was not matched by the objective measures [PMID 16847171].
A larger randomised, evaluator-blinded trial (86 evaluable adults with venous stasis ulcers) compared a topical 0.4% tripeptide copper complex cream, a 1% silver sulfadiazine cream and an inert vehicle. Silver sulfadiazine reduced ulcer size relative to the other two arms, and the abstract reports no difference between the copper complex cream and the vehicle. The abstract does not name the peptide sequence, so it is described only as a tripeptide copper complex [PMID 1495150].
A 2026 critical review of the literature describes the human clinical evidence for GHK-Cu as sparse and notes that historical cosmetic reports are small or incompletely characterised [PMID 42797253]. Multi-ingredient cosmetic or injectable formulations that include a copper tripeptide were not used as evidence here because effects cannot be attributed to GHK-Cu alone.
Preclinical evidence
Cell studies: in cultured fibroblasts, GHK-Cu was reported to stimulate collagen synthesis without a change in cell number [PMID 3169264]. In keratinocyte monolayers and skin-equivalent models, copper-GHK increased proliferation and expression of integrin alpha6 and beta1, p63 and PCNA [PMID 19319546]. These findings come from in vitro systems.
Rat wound models: injections of GHK-Cu into subcutaneous wound chambers produced a concentration-dependent increase in dry weight, DNA, protein, collagen and glycosaminoglycan content compared with saline, whereas a control tripeptide had no significant effect [PMID 8227353]. In a topical study of ischaemic wounds in rats, a tripeptide-copper gel was associated with smaller wound area than no treatment, and lower TNF-alpha, MMP-2 and MMP-9 in wound biopsies [PMID 14648529].
Not every animal study was positive. In irradiated rat dorsal flaps, twice-daily topical GHK-Cu gel for 10 days showed no difference from control in flap ischaemia, blood vessel number or area, or VEGF expression [PMID 23744835].
Inflammation model: in mice with lipopolysaccharide-induced acute lung injury, GHK-Cu was reported to reduce lung histological changes and inflammatory cell infiltration, with reductions in TNF-alpha and IL-6 in cells and animals [PMID 27517151]. This is an animal model of lung injury, not evidence for any human use.
Evidence limitations
Human evidence is limited to a few small or inconclusive topical studies; no verified human data on injected or other systemic use was found.
The one randomised study of GHK-Cu skin care that was verified (13 completers) found no objective benefit and only a self-reported one, and the 86-patient ulcer trial reported no difference from vehicle.
Most mechanistic claims rest on cell cultures and rodent models, and several come from overlapping authors and computational gene-expression analysis.
Formulations are inconsistently characterised: reviews note that copper occupancy, speciation and the amount of intact GHK-Cu delivered are often not defined, which makes results hard to compare.
The age-related decline of circulating GHK is reported in reviews; whether it has any causal role in ageing or tissue repair has not been shown.
Long-term safety, human pharmacokinetics and dose-response have not been established for any route.
A 2026 review concludes GHK-Cu should be regarded as a promising but unproven therapeutic cargo rather than a clinically validated regenerative drug.
Research and regulatory status
A ClinicalTrials.gov search found one registered phase 2 study, NCT07437586, of a topical 0.1% GHK-Cu gel on standardised small skin wounds in healthy adults (60 planned participants, sponsor Hudson Biotech, start date 2026-02-02, status recruiting); no results were posted. No registered trial of injected GHK-Cu was found in this search. GHK-Cu regulatory status as a medicine was not verified in this review.
Miller TR, Wagner JD, Baack BR, et al. · Archives of facial plastic surgery · 2006
Design
Randomised controlled trial of topical GHK-Cu skin-care regimen versus regimen without GHK-Cu after CO2 laser resurfacing
Participants / model
Adult patients (PubMed indexing: middle-aged and aged) undergoing circumoral CO2 laser skin resurfacing; topical application
Sample size
13 patients completed the study
Principal findings
Computer analysis and blinded evaluators observed no statistically significant difference between groups in erythema resolution, wrinkles or overall skin quality. A patient questionnaire reported significantly higher overall skin quality in the GHK-Cu group (P = .04).
Limitations
Very small sample, with a mismatch between objective results and the self-reported outcome. The abstract does not describe the product formulation, so exposure is unclear.
Adults with venous stasis ulcers (PubMed indexing: adult, middle-aged and aged); topical application
Sample size
86 evaluable patients
Principal findings
Silver sulfadiazine cream significantly reduced ulcer size compared with the tripeptide copper complex cream and with vehicle; no difference was reported between the copper complex cream and the vehicle.
Limitations
The abstract refers to a 'biologically active tripeptide copper complex' without naming the sequence, so it is assumed but not confirmed here to be GHK-Cu. Older trial; the formulation and dosing are not detailed in the abstract.
GHK-Cu injection into the wound chamber was associated with a concentration-dependent increase in dry weight, DNA, total protein, collagen and glycosaminoglycan content. Type I and III collagen mRNAs increased, TGF-beta mRNAs did not, and a control tripeptide had no significant effect.
Limitations
Injection directly into an implanted chamber is an experimental model and does not represent human exposure. Group sizes are not given in the abstract.
Maquart FX, Pickart L, Laurent M, et al. · FEBS letters · 1988
Design
In vitro fibroblast culture study
Participants / model
Cultured fibroblasts (species and source not stated in the abstract)
Sample size
not stated in the abstract
Principal findings
GHK-Cu stimulated collagen synthesis by fibroblasts from about 10^-12 to 10^-11 M, maximal at 10^-9 M, independent of any change in cell number. The authors noted a GHK triplet in the alpha-2(I) chain of type I collagen and suggested the tripeptide might be liberated by proteases at a wound site.
Limitations
Cell culture only; the matricryptin idea is a suggestion by the authors rather than a demonstrated mechanism in people. Concentrations used in culture do not map to tissue exposure.
Kang YA, Choi HR, Na JI, et al. · Archives of dermatological research · 2009
Design
In vitro keratinocyte monolayer and skin-equivalent model study
Participants / model
Cultured keratinocytes and skin-equivalent models (source species not stated in the abstract)
Sample size
not stated in the abstract
Principal findings
Copper-GHK increased keratinocyte proliferation in monolayer culture. In skin-equivalent models it was associated with higher PCNA and p63 positivity and increased integrin alpha6 and beta1 expression.
Limitations
In vitro models only; interpretation that it supports basal stem cells is the authors' suggestion and has not been tested in vivo.
Canapp SO, Farese JP, Schultz GS, et al. · Veterinary surgery : VS · 2003
Design
Experimental rat study with topical tripeptide-copper complex gel, vehicle and untreated groups
Participants / model
Adult male Sprague-Dawley rats; full-thickness wounds within an ischaemic skin flap
Sample size
24 rats
Principal findings
Wound area was significantly smaller in the treated group than in controls at several time points (day 13: 64.5% decrease versus 28.2% in untreated and 45.6% in vehicle). Treated wounds had lower TNF-alpha, MMP-2 and MMP-9 concentrations than controls.
Limitations
Small rat study using a commercial gel formulation described in the abstract; results in rodent ischaemic wounds may not translate to human wounds.
Parker NP, Ardeshirpour F, Schmechel SC, et al. · Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery · 2013
Design
Animal model: topical GHK-Cu gel versus aquaphilic ointment control on irradiated dorsal flaps for 10 days
Participants / model
Sprague-Dawley rats after dorsal irradiation
Sample size
13 test and 10 control animals
Principal findings
Treated flaps showed no statistically significant difference from controls in ischaemic area (mean 5.0 versus 3.8 cm2, P = .011, which did not meet the study's P < .01 threshold), in blood vessel number or area, or in VEGF expression.
Limitations
A small rat study with a null result on the primary measures, which tempers positive findings from other models. Flap area was numerically larger, not smaller, in the treated group.
Park JR, Lee H, Kim SI, et al. · Oncotarget · 2016
Design
In vitro macrophage experiments and a mouse model of LPS-induced acute lung injury
Participants / model
LPS-stimulated RAW 264.7 macrophages and mice
Sample size
not stated in the abstract
Principal findings
GHK-Cu was reported to reduce ROS production and TNF-alpha and IL-6, with suppression of NF-kB p65 and p38 MAPK signalling, and to attenuate lung histological changes and inflammatory cell infiltration in the mouse model.
Limitations
Cell line and acute mouse injury model; the route and dosing are not stated in the abstract and the findings do not show any effect in humans.
Pickart L, Vasquez-Soltero JM, Margolina A · BioMed research international · 2015
Design
Narrative review
Participants / model
Summarises in vitro, animal and cosmetic-product studies of GHK and GHK-Cu in skin
Sample size
not applicable (review)
Principal findings
The review states that GHK is present in human plasma, saliva and urine and declines with age, and summarises reports of effects on collagen and glycosaminoglycan synthesis, metalloproteinases, wound healing in several species, and cosmetic outcomes. It also reports that GHK can modulate at least 4,000 human genes.
Limitations
Narrative review; the abstract does not describe how studies were selected. The same authors have published several related GHK reviews.
Pickart L, Margolina A · International journal of molecular sciences · 2018
Design
Narrative review
Participants / model
Summarises cellular, animal and gene-expression data on GHK and GHK-Cu
Sample size
not applicable (review)
Principal findings
The review describes reported effects of GHK on blood vessel and nerve outgrowth, extracellular matrix synthesis, tissue repair in several organs, and anti-inflammatory and cell-protective actions, and proposes that recent gene-expression data may explain these diverse actions.
Limitations
Narrative review; the abstract does not describe how studies were selected, and claims from cell and animal work are not established in humans. Overlapping authorship with other GHK reviews.
Structured systematic evidence-mapping review without quantitative pooling
Participants / model
PubMed, Europe PMC, ClinicalTrials.gov and regulatory sources searched through 12 August 2026
Sample size
not applicable (review)
Principal findings
Reports that preclinical data consistently support effects on matrix remodelling, epithelial repair, inflammatory and redox regulation and angiogenesis, but clinical evidence is sparse, with a 13-participant post-CO2-laser study negative on objective endpoints. It concludes that GHK-Cu should be regarded as a promising but unproven therapeutic cargo rather than a clinically validated regenerative drug.
Limitations
Authors' own two-axis grading framework rather than a standard instrument; no quantitative pooling was possible. Published in 2026, so it has had little time to be assessed by others.